Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial

Area of Science:

• Hepatology
• Medical Oncology
• Immunotherapy

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in certain Asian populations.
• Inoperable HCC presents limited treatment options and a poor prognosis.
• The potential of interferon-alpha as a therapeutic agent for HCC requires further clinical evaluation.

Purpose of the Study:

• To assess the clinical efficacy of recombinant interferon-alpha 2a in Chinese patients with inoperable hepatocellular carcinoma.
• To compare survival rates and tumor response between patients receiving interferon-alpha and those receiving no antitumor therapy.
• To evaluate the safety and tolerability of high-dose interferon-alpha therapy in this cohort.

Main Methods:

• A randomized controlled trial involving 71 adult Chinese patients with histologically confirmed inoperable HCC.
• Intervention group received recombinant interferon-alpha 2a (50 x 10(6) IU/m2) intramuscularly three times weekly (n=35).
• Control group received no antitumor therapy (n=36).
• Clinical efficacy was measured by survival duration and objective tumor regression.
• Adverse events and dosage modifications were recorded to assess tolerability.

Main Results:

• Interferon-alpha treatment significantly improved patient survival compared to the control group (p=0.0471), with median survival of 14.5 weeks versus 7.5 weeks.
• Objective tumor regression (>50%) was observed in 31.4% of interferon-alpha treated patients.
• The interferon-alpha group showed significantly more tumor regression (p<0.0001) and less tumor progression (p=0.001) than the control group.
• Therapy was relatively well-tolerated, with 34.3% requiring dosage reduction due to fatigue.
• Two patients experienced mental deterioration potentially linked to interferon-alpha.

Conclusions:

• Recombinant interferon-alpha 2a therapy is effective in prolonging survival for a subset of Chinese patients with inoperable hepatocellular carcinoma.
• Interferon-alpha demonstrates significant tumor regression capabilities in this patient population.
• High-dose interferon-alpha is a viable therapeutic option for inoperable HCC, offering both survival and tumor response benefits, though careful monitoring for side effects is warranted.